<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885973</url>
  </required_header>
  <id_info>
    <org_study_id>18-01-0060</org_study_id>
    <nct_id>NCT03885973</nct_id>
  </id_info>
  <brief_title>Lactobacillus Plantarum IS 10560 Supplementation in Women With Functional Constipation</brief_title>
  <official_title>Lactobacillus Plantarum IS 10560 Supplementation in Women With Functional Constipation: Molecular Profile of Fecal Microbiome With NGS Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators measured the SCFA (Butyrate, Acetate and Propionate) as a
      Biomarker improvement symptom and quality of life women with functional constipation after
      supplementation of commensal bacterial fermented milk Lactobacillus plantarum (isolated from
      indigenous probiotics from Dadih, West Sumatra) for 21 days
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2018</start_date>
  <completion_date type="Actual">August 22, 2018</completion_date>
  <primary_completion_date type="Actual">August 22, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Chain Fatty Acid (SCFA) titer</measure>
    <time_frame>Three weeks after intervention</time_frame>
    <description>Short Chain Fatty Acid (SCFA) titer that will be analyzed by Gas chromatography-mass spectrometry (GCMS) consists of three metabolites:
Butyrate will be shown in mM unit measure, higher value represents better outcome
Acetate will be shown in mM unit measure, higher value represents better outcome
Proprionate will be shown in mM unit measure, higher value represents better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional constipation symptom improvement (1)</measure>
    <time_frame>Three weeks after intervention</time_frame>
    <description>Functional constipation symptom improvement (1) will be measured by improvement of PAC Sym questionnaire score. PAC Sym (Patient Assessment of Constipation Symptoms) has a minimum score of 0, maximum score 48, lower value represents better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional constipation symptom improvement (2)</measure>
    <time_frame>Three weeks after intervention</time_frame>
    <description>Functional constipation symptom improvement (2) will be measured by improvement of PAC QoL questionnaire score. PAC QoL (Patient Assessment of Constipation Quality of Life) has a minimum score of -20, maximum score 92, lower value represents better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular Profile of Fecal Microbiome</measure>
    <time_frame>Three weeks after intervention</time_frame>
    <description>Microbiome profile from faecal samples will be analyzed with NGS (Next Gen Sequencing) method. The result will be analyzed with MiSEq Reporter software (MSR) and will be presented in nM unit measure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Constipation - Functional</condition>
  <arm_group>
    <arm_group_label>Lactobacillus plantarum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus plantarum</intervention_name>
    <description>Fermented milk containing probiotic Lactobacillus plantarum for three weeks</description>
    <arm_group_label>Lactobacillus plantarum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fermented milk containing placebo for three weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being declared healthy based on initial examination and the Structured Interview
             Questionnaire (SIQ)

          -  Having the symptoms and signs of functional constipation refer to ROME IV

          -  Able to communicate well

          -  Able to consume 1 bottle of fermented milk each day for three weeks

          -  Not using antibiotic no later than one week before supplementation

        Exclusion Criteria:

          -  Diagnosed with functional bowel disorder

          -  Using anesthesia at least 4 weeks before treatment

          -  Having a serious pathological disorder (carcinoma)

          -  During healing phase of acute gastrointestinal disorders at least 4 weeks before
             treatment

          -  Having severe heart disease

          -  Taking chronic medications such as antidepressants or analgesics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pratiwi D Kusumo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puskesmas Petamburan</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11440</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Murdani Abdullah</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>SCFA</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Lactobacillus plantarum</keyword>
  <keyword>Functional constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03885973/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

